MGC Pharma

APRIL 4, 2018

A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals. CBD-based treatment for people with Refractory Epilepsy?—?is Refractory Epilepsy is epilepsy that involves frequent and severe seizures that are difficult to treat. CannEpil™?—?CBD-based

Epilepsy 100

Epilepsy Pharmaceutical Research and Development CBD 100

Cannabis Law Report

JANUARY 15, 2019

British firm GW Pharmaceuticals is licking its wounds after US judges tossed out its attempt to patent multiple cannabinoids for epilepsy treatment following an eight-year battle. The patent, which has been embroiled in dispute since 2010, is for “the use of one or more cannabinoids in the treatment of epilepsy”.

Epilepsy 71

Epilepsy Cannabinoids Treatment Research and Development 71

Cannabis Law Report

DECEMBER 23, 2021

DUBLIN–(BUSINESS WIRE)– “The Pharmaceutical Cannabis Report: 2nd Edition” report has been added to ResearchAndMarkets.com’s offering. In both Europe and the United States, the sales of unapproved cannabis products such as smokable flower and full spectrum oils dwarf those of approved pharmaceuticals.

Pharmaceutical 74

Pharmaceutical Clinical Trials Research and Development Cannabinoids 74

WeedAdvisor

JANUARY 8, 2019

For decades, marijuana for cancer treatment seemed out of the question. Even if trials were successful, it is safe to say that using marijuana to treat cancer would meet resistance from the pharmaceutical companies and medical communities alike. The Endocannabinoid System in Cannabis Cancer Treatment.

Treatment 75

Treatment Research and Development Cannabinoids THC 75

Cannabis Law Report

AUGUST 17, 2021

.–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. We look forward to initiating our Phase 3 trial and adding to the body of evidence that supports ganaxolone’s potential as an innovative treatment option for rare epilepsies.”. Chief Medical Officer of Marinus. “We Data Highlights.

Pharmaceutical 76

Pharmaceutical Clinical Trials Treatment Patients 76

Puff Puff Post

DECEMBER 28, 2018

Influencing how information is processed and how nerve cells and synapses in the brain interact, the exact function related to autism is still not well understood, and no pharmaceuticals around yet can ‘fix’ autism. The Current Treatments for Autism. As it sits, only a few methods of treating autism are available.

Treatment 76

Treatment Oil CBD Therapy 76

MMJ Recs

NOVEMBER 20, 2023

Epilepsy Management: CBD, in particular, has emerged as an effective treatment for epilepsy, especially in individuals with rare and severe forms of the condition. Neurological Disorders: Several cannabinoids show promise in the treatment of neurological disorders, including multiple sclerosis (MS) and Parkinson’s disease.

Cannabinoids 98

Cannabinoids Epilepsy Treatment Marijuana 98

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. What about other medical cannabis products? What do experts say? September 23, 2019.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

MGC Pharma

FEBRUARY 15, 2018

A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals Right now in Australia, access to Cannabis-based treatments is heavily restricted. Physicians who want to prescribe Medicinal Cannabis are required to jump through countless regulatory hoops, as are patients seeking treatment.

Access 100

Access Medicine Chronic Pain Research and Development 100

Cannabis Law Report

JULY 12, 2019

Ultimately, the cannabinoid system works by way of multiple molecules affecting multiple receptors at once – the entourage effect, and thus such singular approaches to treatment by way of the cannabinoid system are not effective. An Israeli study of cannabis versus epilepsy, however, used natural extracts with a ratio of 20:1 CBD:THC.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

Cannabis Law Report

AUGUST 24, 2021

BALTIMORE–(BUSINESS WIRE)– $MYMD — MyMD Pharmaceuticals, Inc. “Nearly 100,000 people in the United States have idiopathic pulmonary fibrosis (IPF), and although cases continue to climb, there is still a significant unmet need in treatment options for this chronic disease,” said Chris Chapman, M.D.,

Pharmaceutical 75

Pharmaceutical Clinical Trials Chronic Pain CBD 75

WeedAdvisor

SEPTEMBER 24, 2019

GW Pharmaceuticals created the medication after studies showed surprising success treating severe childhood epilepsy, specifically Lennox-Gastaut Syndrome and Dravet Syndrome. Dravet and LGS are also notoriously resistant to conventional treatment, leaving many children unable to live normal lives due to multiple daily seizures.

Epilepsy 49

Epilepsy CBD Pharmaceutical Access 49

Veriheal

SEPTEMBER 16, 2020

Epidiolex is the sole cannabis-derived pharmaceutical that has been approved by the FDA – although it is worth noting that the organization has also approved three synthetic cannabis-related products. The FDA Adds a New Condition for Treatment. However, there is one notable example—Epidiolex. What is Epidiolex?

Access 98

Access Epilepsy Treatment Conditions 98

Cannabis Law Report

JULY 26, 2021

SciSparc intends to evaluate the efficacy, safety and tolerability of its Proprietary Cannabinoid-Based Treatment- SCI-110. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. TEL AVIV, Israel , July 26, 2021 /PRNewswire/ — SciSparc Ltd.

Research and Development 105

Research and Development Supply Chain Pharmaceutical Treatment 105

Peninsula Alternative Health

MAY 15, 2019

Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy. tetrahydrocannabinol (THC).

Conditions 89

Conditions Therapy Cannabinoids Epilepsy 89

MGC Pharma

DECEMBER 12, 2017

A word from Elad Segev, Manager of Breeding and Cultivation at MGC Pharmaceuticals. This effect can be put to very good use to help patients suffering from cancer or HIV/AIDS eliminate any uncomfortable nausea that their treatments provoke. It’s also effective in treating patients with refractory epilepsy who experience daily seizures.

Epilepsy 100

Epilepsy Pharmaceutical Cannabinoids THC 100

Cannabis Law Report

DECEMBER 3, 2021

.–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Chief Executive Officer of Marinus Pharmaceuticals. “We Extended Duration Safety and Efficacy of Adjunctive Ganaxolone Treatment in Patients with CDKL5 Deficiency Disorder: 8-Month Minimum Open-Label Extension Follow-up. change in MMSF).

Epilepsy 40

Epilepsy Pharmaceutical Data Clinical Trials 40

Cannabis Law Report

JANUARY 16, 2022

Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) previously approved a prescription medicine derived from cannabis in 2014 to treat muscle spasms and spasticity from multiple sclerosis. Sativex was developed by GW Pharmaceuticals, a maker of cannabinoid therapeutics based in Ireland.

Pharmaceutical 98

Pharmaceutical Research and Development Epilepsy Medicine 98

Cannabis Law Report

JULY 30, 2019

Following an encouraging initial US launch, GW Pharmaceuticals’s cannabidiol oral solution is also set to achieve European approval later in 2019. The US approval of Zogenix’s Fintepla, a potential competitor for GW’s drug, has been delayed but still lo… The European Pharmaceutical Review reports.

Epilepsy 40

Epilepsy Pharmaceutical Medicine Treatment 40

Cannabis Law Report

AUGUST 20, 2021

SLSG and its Swiss subsidiary, Savim SA , are developing specific proprietary strains of cannabis, with a focus on various areas, but particularly on future medical treatments for a variety of illnesses and diseases, including epilepsy, autism, and the different stages of COVID-19.

Research and Development 116

Research and Development Strains Treatment Epilepsy 116

Puff Puff Post

OCTOBER 3, 2019

Previous success from treating epilepsy with Cannabinoids now motivates doctors to investigate the plant’s effectiveness in treating symptoms of autism. Montefiore Medical Center in New York and GW Pharmaceuticals are examining the effects of a cannabis compound when administered to children on the autism spectrum.

Research and Development 94

Research and Development Epilepsy Clinical Trials Treatment 94

Veriheal

SEPTEMBER 27, 2021

Medical cannabis has been legal in the nation for almost three years—so why are MS patients struggling to access the treatment? 1, MS Society UK posted on Twitter , “Getting the treatment you need shouldn’t be a game of chance. It’s this line of thought that contributed to the drive for launching a campaign. . ApprovedButDenied.

Treatment 98

Treatment Patients Access Research and Development 98

Cannabis Law Report

SEPTEMBER 28, 2021

DUBLIN–(BUSINESS WIRE)–The “Epilepsy – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering. This Epilepsy – Pipeline Insight, 2021 provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Epilepsy pipeline landscape.

Epilepsy 40

Epilepsy Clinical Trials Research and Development Pharmaceutical 40

MMJ Recs

NOVEMBER 17, 2023

By legalizing MMJ, the state has facilitated access to a natural and potentially life-changing treatment option for patients suffering from various medical conditions. Support for Patient Well-Being The availability of medical marijuana in local communities fosters an environment of support for patients seeking alternative treatments.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Otherside Farms

JANUARY 24, 2019

Federal regulators have approved two clinical studies testing whether a marijuana-based epilepsy drug may help prevent seizures among epileptic children. Source: FDA Approves Marijuana-Based Epilepsy Drug For Use On Kids In Clinical Trials. Although both studies will enroll 25 patients initially, the U.S. In the upcoming U.S.

Clinical Trials 45

Clinical Trials Epilepsy Marijuana Pharmaceutical 45

Cannabis Law Report

AUGUST 2, 2021

OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain. TEL AVIV, Israel , Aug. ” About The Study.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

JUNE 5, 2019

Press Release: Thailand Government Pharmaceutical Organization. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths. 30 May 2019.

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40

Canna Law Blog

MARCH 12, 2019

9,066,920 – “Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy” (“the 920 Patent”). GW Pharma”) and Otsuka Pharmaceuticals Co., Epidiolex was approved to treat two rare forms of epilepsy: Dravet syndrome and Lennox-Gastaut syndrome. In this case, the subject patent was U.S.

Epilepsy 87

Epilepsy Pharmaceutical Cannabinoids CBD 87

Cannabis Law Report

SEPTEMBER 28, 2021

Acupuncture is one of the safest alternative forms of treatment for chronic pain. Ideally, it should be used in combination with other therapies, such as herbal medicine and massage, and can be a great addition to other treatments. Radio Frequency Treatment. Acupuncture. First, you need to find a certified acupuncturist.

Treatment 52

Treatment Chronic Pain Therapy Tincture 52

Kind Meds (Cannabis Education Blog)

JANUARY 9, 2019

Medical marijuana laws have changed dramatically across the country in recent years, and now cannabis pharmaceuticals appear to be the next big leap forward in cannabis law reform. Epidiolex has received FDA approval to treat Dravet Syndrome and Lennox-Gestaut Syndrome; two very rare forms of epilepsy that manifest in early childhood.

Research and Development 97

Research and Development Treatment Pharmaceutical Conditions 97

United Patients Group

APRIL 18, 2023

Because they often combine it with other drugs like cocaine or heroin or even legal ‘prescribed’ pharmaceuticals–and those are far more dangerous than cannabis itself! The same cannot be said for alcohol or even caffeine (a more dangerous drug), which can lead to death if consumed excessively enough over time.

Research and Development 116

Research and Development Indica Treatment Conditions 116

Cannabis Law Report

SEPTEMBER 29, 2022

Australia’s drugs regulator issues 73 infringement notices over claims prescriptions could treat conditions such as cancer and epilepsy. The Therapeutic Goods Administration (TGA) issued 73 infringement notices totalling $972,360 between the medicinal cannabis companies MGC Pharmaceuticals Ltd, Cannatrek Ltd and Little Green Pharma Ltd.

Epilepsy 52

Epilepsy Conditions Media Medicine 52

The Cannigma

JUNE 15, 2021

The first clinical research done on CBD as a potential treatment for epilepsy was in 1980, but the information gleaned didn’t make its way to the public eye until decades later. CBG, however, also has some medicinal potential that CBD doesn’t, for instance as a treatment for hypertension and insulin resistance. Shutterstock).

CBD 122

CBD Research and Development Epilepsy Extraction 122

Veriheal

FEBRUARY 21, 2023

Despite notable advances in MMJ research over the last decade, scientists have found that some states’ restrictions on qualifying conditions prevent millions of patients from getting the treatments they need—robbing them of potential relief offered by cannabinoid therapies. Why Do MMJ Patients Use Cannabis?

Access 98

Access Patients Chronic Pain Conditions 98

MedicalJane

OCTOBER 3, 2019

The United States Department of Defense and GW Pharmaceuticals are collaborating on a new clinical trial at the Montefiore Medical Center in New York. Epidiolex is indicated for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older.

Clinical Trials 74

Clinical Trials Epilepsy Pharmaceutical Treatment 74

Project CBD

FEBRUARY 28, 2023

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Epilepsy Behav. Accessed October 17, 2022.

CBD 144

CBD Seed-To-Sale Food Access 144

CannaTech

JANUARY 16, 2019

Pharmaceutical grade cannabis is relatively new in parts of the world. Patients, and their treatment, therefore, are the priority. Treatment options may be limited by government-approved imports, a practitioner’s prescription or pharmacy stock. It is not a story about profiting off of people. million people.

Access 89

Access Patients Pharmaceutical Education 89